ACTIVITY OF THE EPIPODOPHYLLOTOXIN VP-16 IN THE TREATMENT OF COMBINATION CHEMOTHERAPY-RESISTANT NON-HODGKIN LYMPHOMA

[1] ANDERSON T, 1977, CANCER TREAT REP, V61, P1057

[2] BERARD CW, 1972, PRINCIPLES HEMATOLOG, P901

[3] CREAVEN PJ, 1974, CANCER CHEMOTH REP 1, V58, P901

[4] FALKSON G, 1975, CANCER, V35, P1141, DOI 10.1002/1097-0142(197504)35:4<1141::AID-CNCR2820350418>3.0.CO

[5] 2-3

[6] JACOBS P, 1975, S AFR MED J, V49, P483

[7] JOHNSON RE, 1975, CANCER, V35, P242, DOI 10.1002/1097-0142(197501)35:1<242::AID-CNCR2820350129>3.0.CO

[8] 2-H

[9] KING L, 1946, SCIENCE, V10, P244

[10] MATHE G, 1974, CANCER-AM CANCER SOC, V34, P985, DOI 10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO

[1] ANDERSON T, 1977, CANCER TREAT REP, V61, P1057

[2] BERARD CW, 1972, PRINCIPLES HEMATOLOG, P901

[3] CREAVEN PJ, 1974, CANCER CHEMOTH REP 1, V58, P901

[4] FALKSON G, 1975, CANCER, V35, P1141, DOI 10.1002/1097-0142(197504)35:4<1141::AID-CNCR2820350418>3.0.CO

[5] 2-3

[6] JACOBS P, 1975, S AFR MED J, V49, P483

[7] JOHNSON RE, 1975, CANCER, V35, P242, DOI 10.1002/1097-0142(197501)35:1<242::AID-CNCR2820350129>3.0.CO

[8] 2-H

[9] KING L, 1946, SCIENCE, V10, P244

[10] MATHE G, 1974, CANCER-AM CANCER SOC, V34, P985, DOI 10.1002/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO